PACTR201909502724014

Intralesional Steroid Injection versus Erbium Yttrium Aluminium Garnet Laser Assisted Topical Corticosteroid Delivery in Treatment of Keloids.

Dina Hassan Abdeldayem·Phase 1·Pan Africa Clinical Trials Registry·otherCompleted
Study focus
Intervention type
other
Sponsor & location
Primary sponsor
Dina Hassan Abdeldayem
Funder
Dina Hassan Abdel Dayem
Location
Egypt
Timeline & enrollment
Phase
Phase 1
Start date
Aug 08, 2018
End date
Feb 07, 2019
Summary

Keloid scars are often considered aesthetically unattractive and frustrating problem that cause functional and cosmetic deformities, displeasure, itching, pain, and psychological stress and may possibly affect joint movement (Trisliana et al., 2014).With limited knowledge about the actual causes of keloids, determining the most effective treatment has been challenging. Various methods have been implemented to improve keloid scars using both surgical and non-surgical approaches such as intralesional corticosteroid injections, fractional lasers, cryosurgery, 5-fluorouracil (5-FU), retinoic acid, imiquimod 5% cream (an immune response modifier that enhances healing, has also been used to help prevent keloid recurrence after surgical excision)., tamoxifen, tacrolimus, botulinum toxin, silicone sheets (Berman, 2017).Fractional lasers have emerged as a therapeutic option for the aesthetic restoration and functional enhancement of traumatic scars. They create zones of ablation at variable depths, which induce a molecular cascade, including heat shock proteins and other factors that lead to a rapid healing response and prolonged neocollagenesis with subsequent collagen remodeling. The likely result is the removal of a portion of fibrotic scar tissue and a relative normalization of collagen structure and composition (Cavalié et al., 2015).Aim of studyTo compare a combination treatment modality consisting of fractional ablative laser treatment and topical corticosteroid application to the standard modality of corticosteroid intralesional injection.

ICD-10 classifications
Systemic disorders of connective tissue in diseases classified elsewhereSystemic disorders of connective tissue in other diseases classified elsewhereDiseases of the skin and subcutaneous tissueOther disorders of skin and subcutaneous tissue in diseases classified elsewhereOther disorders of the skin and subcutaneous tissue
Data source
Registry
Pan Africa Clinical Trials Registry
Trial ID
PACTR201909502724014
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for PACTR201909502724014 through Pure Global AI's free database. This Phase 1 trial is sponsored by Dina Hassan Abdeldayem and is currently Completed. The study focuses on Skin and Connective Tissue Diseases.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to Pan Africa Clinical Trials Registry data, helping medical device and pharmaceutical companies navigate clinical research efficiently.